Wetter esse n trial#

Conclusion: Despite 70% concordance with CI, PSMA PET demonstrated superior reproducibility and accuracy especially for non-metastatic CRPC and should be implemented in future clinical trial entry procedures. Agreement for PET versus CI PCWG3 clinical subtypes was 0.81 versus 0.51, 0.74 versus 0.47, 0.95 versus 0.72, or 0.59 versus 0.66 for local, nodal, bone, or visceral disease, respectively. PSMA PET resulted in down-staging in 15% (10/67) of patients. Results: Sixty-seven patients were included, and PSMA PET led to up-staging in 15% (10/67) of patients of these, 6 of 10 (60%) had nonmetastatic CRPC on CI.

The clinical PCWG3 subtype was determined for PET versus CI by 3 masked readers.

Methods: A multicenter retrospective study enrolled patients who had undergone PSMA PET for CRPC, had prostate-specific antigen values of at least 1 ng/mL, and had undergone CI-that is, CT plus bone scanning or whole-body MRI. We investigated the impact of PSMA PET on Prostate Cancer Clinical Trials Working Group 3 (PCWG3) clinical subtype classification when compared with conventional imaging (CI).

Prostate-specific membrane antigen (PSMA)-ligand PET is potentially useful for screening of castration-resistant prostate cancer (CRPC) clinical trial target populations. Auf der interaktiven Wetterkarte von The Weather Channel und können Sie schwenken und zoomen, um die genauesten Wetterinformationen für Ihre Gegend oder einen Ort auf der anderen.